Rochester, Minn.-based Mayo Clinic researchers have developed an AI echocardiography model that they say can detect cardiac amyloidosis from a single video clip.
The model, created in partnership with an AI echocardiography company, was approved by the FDA as a breakthrough device and is the first commercially available AI echocardiography tool to screen for amyloid cardiomyopathy, according to an Aug. 16 news release.
Study findings published in the European Heart Journal showed the model achieved an area under the receiver operating characteristic curve of 0.93, with 85% sensitivity, 93% specificity, a positive predictive value of 78% and a negative predictive value of 96%. Researchers found that 0.53% of patients receiving echocardiograms displayed features suggestive of amyloid cardiomyopathy but were not evaluated with confirmatory testing.
Cardiac amyloidosis, a progressive and rare form of heart failure, is often difficult to diagnose because its symptoms resemble other conditions. About 15% of patients with heart failure with preserved ejection fraction have cardiac amyloidosis.
The technology is already in use at multiple U.S. centers and may be implemented in any echocardiography lab to improve screening accuracy for cardiac amyloid.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
